A phase 1b/2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec (T-VEC) injected into primary and metastatic liver tumors alone and in combination with pembrolizumab (pembro) (MASTERKEY-318).
2018 ◽
Vol 36
(15_suppl)
◽
pp. TPS3105-TPS3105
◽
Keyword(s):
Phase 1B
◽
2015 ◽
Vol 3
(S2)
◽
2001 ◽
Vol 45
(2)
◽
pp. 147
The Diagnostic Value of Cytokeratin 7 and 20 in Determination of Primary and Metastatic Liver Tumors
2015 ◽
Vol 25
(1)
◽
Keyword(s):
1982 ◽
Vol 12
(6)
◽
pp. 456-462
◽
Keyword(s):